"The additional data captured by extended continuous cardiac monitoring allows for a definitive diagnosis in a single test to accelerate care," said Judy Lenane, RN, MHA, executive vice president of operations and chief clinical officer of iRhythm Technologies, Inc. "This research adds to the growing body of scientific evidence showing the advantages of extended continuous monitoring in detecting arrhythmias over time. Utilizing iRhythm's unique data warehouse and cloud-based analytics platform, the reliable and clinically actionable information provides a path forward."About iRhythm Technologies, Inc. iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company's platform, the Zio Service, has been provided to over 500,000 patients, accumulating more than 125 million hours of curated heartbeat data within iRhythm's data repository.
Investor Relations ContactLynn Pieper Lewis or Leigh Salvo(415) firstname.lastname@example.orgMedia ContactAaron Murphy email@example.com 415-229-3331